Drug discovery
The company specializes in progressing innovative research from academia into commercialized products.
Source: LinkedIn company description · Retrieved October 13, 2026
Immunodominant is a drug discovery company that progresses academic research toward commercialized products.
Its lead program focuses on developing orally administered direct-acting antivirals for COVID-19 treatment and prevention. The company uses structural information to identify compounds capable of modifying biological responses, with intellectual property covering therapies for autoimmune diseases and cancer prevention and treatment.
Based on the company’s public LinkedIn information, supplied through RevenueBase.
The company specializes in progressing innovative research from academia into commercialized products.
Source: LinkedIn company description · Retrieved October 13, 2026
Supported appearances on published RevenueBase lists, including available memberships beyond displayed rankings.
Positions describe ordering within each source list. See how lists are built ↗
Embeddable award for your website
RevenueBase prepared this profile from the company’s public LinkedIn information and RevenueBase company data. These source records were retrieved on October 13, 2026. AI helped summarize these sources, with a separate automated check against the source text completed on November 1, 2026. Directory positions use company-contact counts from separate saved list snapshots dated September 15, 2026. How the company lists are built.
Share a correction, your relationship to the company, and supporting sources. Requests are reviewed before changes are published.
Explore more companies by name, headquarters and business focus.